Zobrazeno 1 - 10
of 219
pro vyhledávání: '"Darius N Lakdawalla"'
Publikováno v:
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, Vol 8, Iss 1, Pp n/a-n/a (2022)
Abstract Introduction The U.S. Food and Drug Administration (FDA)'s guidances help describe the agency's current thinking on regulatory issues and serve as a means of informal policymaking that is non‐binding. This study examines the impact of two
Externí odkaz:
https://doaj.org/article/ccfa05ce0c8e46e28a0c63e0fded3f22
Publikováno v:
Journal of Benefit-Cost Analysis. :1-24
The generalized risk-adjusted cost-effectiveness (GRACE) analysis method modifies standard cost-effectiveness analysis (CEA), the primary method currently used worldwide to value health improvements arising from healthcare interventions. Generalizing
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::af22f4d8e721b51eae454f70f2390074
https://doi.org/10.1017/bca.2023.6
https://doi.org/10.1017/bca.2023.6
Publikováno v:
Value in Health. 25:1828-1836
Aduhelm is the first approved disease-modifying therapies (DMT) for Alzheimer disease (AD). Nevertheless, under current payment models, AD DMTs-especially because they treat broader populations-will pose challenges to patient access since costs may a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e24b23ec8f1a49c4af1406eb646b8a3
https://doi.org/10.1016/j.jval.2022.06.003
https://doi.org/10.1016/j.jval.2022.06.003
Publikováno v:
Value in Health.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::08e741cc1f13761fa568eaa14bc1b3e0
https://doi.org/10.1016/j.jval.2023.02.001
https://doi.org/10.1016/j.jval.2023.02.001
Publikováno v:
Annals of Internal Medicine. 174:1700-1709
Background Fully assessing the mortality burden of the COVID-19 pandemic requires measuring years of life lost (YLLs) and accounting for quality-of-life differences. Objective To measure YLLs and quality-adjusted life-years (QALYs) lost from the COVI
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5f7618cf37456991101c46e7223a9406
https://doi.org/10.7326/m21-2239
https://doi.org/10.7326/m21-2239
Publikováno v:
The European Journal of Health Economics. 23:433-451
The generalized risk-adjusted cost-effectiveness (GRACE) model generalizes conventional cost-effectiveness analysis (CEA) by introducing diminishing returns to Health-Related Quality of Life (QoL). This changes CEA practice in three ways: (1) Willing
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8fb0a4063c4d106330f566ba05befed7
https://doi.org/10.1007/s10198-021-01367-0
https://doi.org/10.1007/s10198-021-01367-0
Autor:
Darius N. Lakdawalla, Katie Everson, Lauren M Zhao, Dominik Lautsch, Fang Sun, Joanna P. MacEwan, Larry Z. Liu
Publikováno v:
The American Journal of Managed Care. 27:162-168
Objectives To assess the evolving landscape of low-density lipoprotein cholesterol-lowering therapies (LLTs) and quantify their effect on cardiovascular disease (CVD)-related mortality and morbidity. Study design Secondary data came from LLT clinical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::539f9d01ca3bde8a6a4cf3a70c3b6456
https://doi.org/10.37765/ajmc.2021.88618
https://doi.org/10.37765/ajmc.2021.88618
Publikováno v:
JAMA Network Open. 6:e2315823
ImportancePrior research suggests significant social value associated with increased longevity due to preventing and treating cancer. Other social costs associated with cancer, such as unemployment, public medical spending, and public assistance, may
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::01d6a84b21f6312eb3ba59d0bac0fb3e
https://doi.org/10.1001/jamanetworkopen.2023.15823
https://doi.org/10.1001/jamanetworkopen.2023.15823
Publikováno v:
Eur J Health Econ
Pharmaceuticals are priced uniformly by convention, but vary in their degree of effectiveness for different disease indications. As more high-cost therapies have launched, the demand for alternative payment models (APMs) has been increasing in many a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62e241aa09daada822fdcc74e6015878
https://doi.org/10.1007/s10198-021-01274-4
https://doi.org/10.1007/s10198-021-01274-4
Autor:
Gary R, Lichtenstein, Ahva, Shahabi, Seth A, Seabury, Darius N, Lakdawalla, Oliver Díaz, Espinosa, Sarah, Green, Michelle, Brauer, Robert N, Baldassano
Publikováno v:
Gastroenterol Hepatol (N Y)
Patients with Crohn’s disease (CD) or ulcerative colitis (UC) have high morbidity rates owing to debilitating intestinal complications and extraintestinal manifestations (EIMs). We retrospectively identified patients in the Truven MarketScan databa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8ffcd73061650eab81a121e14edb9967
https://pubmed.ncbi.nlm.nih.gov/35505770
https://pubmed.ncbi.nlm.nih.gov/35505770